title: Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.
abstract: OBJECTIVE
  The objective of this study is to examine the effect of acarbose, an alpha-glucosidase inhibitor, on body weight in a real-life setting by pooling data from post-marketing surveillance.
  
  
  METHODS
  Data from 10 studies were pooled (n=67,682) and the effect of acarbose on body weight was analysed taking into account baseline body weight, glycemic parameters and other baseline characteristics.
  
  
  RESULTS
  The mean relative reduction in body weight was 1.45 ± 3.24% at the 3-month visit (n=43,510; mean baseline 73.4 kg) and 1.40 ± 3.28% at the last visit (n=54,760; mean baseline 73.6 kg) (both p<0.0001). These reductions were dependent on baseline body weight (overweight: -1.33 ± 2.98% [n=13,498; mean baseline 71.6 kg]; obese: -1.98 ± 3.40% [n=20,216; mean baseline 81.3 kg]). When analysed by baseline glycemic parameter quartiles, the reduction was independent of fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin (HbA1c) and postprandial glucose excursion (PPGE). A bivariate analysis of covariance identified female sex, South East Asian and East Asian ethnicity, younger age, higher body mass index, short duration of diabetes, and no previous treatment as factors likely to impact positively on body weight reduction with acarbose.
  
  
  CONCLUSIONS
  This post-hoc analysis showed that acarbose treatment reduces body weight independent of glycemic control status but dependent on baseline body weight.
authors.affiliation: Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, Munich, Germany. Electronic address: Oliver.Schnell@lrz.uni-muenchen.de.
authors.forename: Oliver
authors.initials: O
authors.lastname: Schnell
authors.affiliation: Guangdong Provincial Key Laboratory of Diabetology, Guangzhou; Department of Endocrinology and Metabolic Disease, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: wengjp@cma.org.cn.
authors.forename: Jianping
authors.initials: J
authors.lastname: Weng
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Electronic address: whhsheu@vghtc.gov.tw.
authors.forename: Wayne H-H
authors.initials: WH
authors.lastname: Sheu
authors.affiliation: Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: hwatada@juntendo.ac.jp.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
authors.affiliation: Bharti Research Institute of Diabetes & Endocrinology, Karnal, India. Electronic address: brideknl@gmail.com.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: University of Indonesia, Jakarta, Indonesia. Electronic address: sidartawansoegondo@me.com.
authors.forename: Sidartawan
authors.initials: S
authors.lastname: Soegondo
authors.affiliation: Bayer HealthCare, Beijing, China. Electronic address: noriyuki.yamamoto@bayer.com.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Yamamoto
authors.affiliation: Bayer HealthCare, Thane, India. Electronic address: rahul.rathod@bayerzyduspharma.com.
authors.forename: Rahul
authors.initials: R
authors.lastname: Rathod
authors.affiliation: Bayer HealthCare, Beijing, China. Electronic address: cheryl.zhang@bayer.com.
authors.forename: Cheryl
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Silesian University of Medicine, Zabrze, Poland. Electronic address: wgrzeszczak@sum.edu.pl.
authors.forename: Wladyslaw
authors.initials: W
authors.lastname: Grzeszczak
mesh_terms: D020909:Acarbose / Q000009:adverse effects / Q000627:therapeutic use*; D000367:Age Factors; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D014943:Global Health / Q000208:ethnology; D065089:Glycoside Hydrolase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D064887:Observational Studies as Topic; D050177:Overweight / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D011358:Product Surveillance, Postmarketing; D012727:Sex Characteristics; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D065089:Glycoside Hydrolase Inhibitors; D020909:Acarbose
keywords: Acarbose; Alpha-glucosidase inhibitor; Body weight; Glycemic control; Type 2 diabetes mellitus